Viewing data from:

LOVASTATIN

ANDA

LOVASTATIN | A075551 | TEVA PHARMACEUTICALS USA INC

3 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 6 NDCs

Highest NADAC/Unit

$0.0558

per ea

Lowest NADAC/Unit

$0.0372

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00093092806LOVASTATIN 40 MG TABLET	$0.0558	EA	Generic	—	2026-08-19
00093092810LOVASTATIN 40 MG TABLET	$0.0558	EA	Generic	—	2026-08-19
00093057606LOVASTATIN 20 MG TABLET	$0.0430	EA	Generic	—	2026-08-19
00093057610LOVASTATIN 20 MG TABLET	$0.0430	EA	Generic	—	2026-08-19
00093092606LOVASTATIN 10 MG TABLET	$0.0372	EA	Generic	—	2026-08-19
00093092610LOVASTATIN 10 MG TABLET	$0.0372	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (3 FSS)

Lowest Price

$29.43

Highest Price

$38.65

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
51407-0251-10LOVASTATIN 10MG TAB	$31.45	FSS	Golden State Medical Supply, Inc.	06/14/2028
51407-0252-10LOVASTATIN 20MG TAB	$29.43	FSS	Golden State Medical Supply, Inc.	06/14/2028
51407-0253-10LOVASTATIN 40MG TAB	$38.65	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain10 active DMFs22 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

TEVA PHARMACEUTICAL INDUSTRIES LTDLOVASTATIN USP

DMF 115021995

ZHEJIANG HISUN PHARMACEUTICAL CO LTDLOVASTATIN USP

DMF 121331996

LUPIN LTDLOVASTATIN USP

DMF 173532004

CONCORD BIOTECH LTDLOVASTATIN USP

DMF 173932004

LUPIN LTDLOVASTATIN TECHNICAL

DMF 177372004

LIVZON GROUP (NINGXIA) PHARMACEUTICAL CO LTDLOVASTATIN (NON-STERILE, BULK FORM)

DMF 185392005

ZHEJIANG APELOA KANGYU PHARMACEUTICAL CO LTDLOVASTATIN USP, NON-STERILE ACTIVE PHARMACEUTICAL INGREDIENT

DMF 192172006

CHONGQING DAXIN PHARMACEUTICAL CO LTDLOVASTATIN

DMF 200612006

STERLING BIOTECH LTDLOVASTATIN(API)

DMF 248592011

CHONGQING DAXIN PHARMACEUTICAL CO LTDLOVASTATIN

DMF 354312020

ANTIBIOTIC COInactiveLOVASTATIN

DMF 113361996

ZHEJIANG RUIBANG LABORATORIES INCInactiveLOVASTATIN

DMF 124001997

SYNGEN BIOTECH CO LTDInactiveLOVASTATIN

DMF 124811997

CHONGQING DAXIN PHARMACEUTICAL CO LTDInactiveLOVASTATIN, USP

DMF 124961997

ABBOTT LABORATORIES CHEMICAL AND AGRICULTURAL PRODUCTS DIVInactiveLOVASTATIN, USP

DMF 132481998

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPAInactiveLOVASTATIN

DMF 139171998

YUNG SHIN PHARMACEUTICAL INDUSTRIES CO LTDInactiveLOVASTATIN

DMF 140491999

LEK PHARMACEUTICAL AND CHEMICAL CO DDInactiveLOVASTATIN ACTIVE DRUG SUBSTANCE

DMF 144021999

RANBAXY LABORATORIES LTDInactiveLOVASTATIN USP

DMF 144701999

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPAInactiveLOVASTATIN

DMF 147842000

BIOCON LTDInactiveLOVASTATIN USP

DMF 149122000

CKD BIO CORPInactiveLOVASTATIN, NON-STERILE BULK, USP

DMF 149212000

BIOCON INDIA LTDInactiveLOVASTATIN TECHNICAL(SFP)

DMF 160952002

ERCROS INDUSTRIAL SA FYSEInactiveLOVASTATIN (TECHNICAL GRADE)

DMF 169012003

ERCROS SAInactiveLOVASTATIN

DMF 170692004

KREBS BIOCHEMICALS INDUSTRIES LTDInactiveLOVASTATIN USP

DMF 171742004

LUPIN LTDInactiveLOVASTATIN

DMF 173102004

CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTDInactiveLOVASTATIN

DMF 174982004

LEK PHARMACEUTICALS DDInactiveLOVASTATIN

DMF 176622004

ZHEJIANG RUIBANG LABORATORIES INCInactiveLOVASTATIN USP

DMF 181882005

SANDOZ INDUSTRIAL PRODUCTS SPAInactiveLOVASTATIN DRUG SUBSTANCE INTERMEDIATE

DMF 193992006

ALEMBIC LTDInactiveLOVASTATIN USP

DMF 280582014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 40MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 17, 2001

No patent or exclusivity listings for this strength.

#002 — 20MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 17, 2001

#003 — 10MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 17, 2001